Orbis Medicines is developing macrocyclic peptides that address a wider range of targets and can be taken as oral pills. Novo Holdings and Forbion are backing the startup, which is based on research from the scientific co-founder of peptide drug developer Bicycle Therapeutics.
The company is developing tumor-infiltrating lymphocyte therapies that target patient-specific neoantigens. It plans to use the money to fund Phase I/IIa studies in solid tumors.
Explore the top mobile IV therapy companies boosting immune health on demand, with standout services, expert care and innovative delivery across the U.S.
The company, focused on epitranscriptomics, launched with backing from Versant Ventures, Forbion, GSK's venture capital arm, Celgene and others.